Cargando…

Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation

Expression of oncogenic Bcr-Abl inhibits cell differentiation of hematopoietic stem/progenitor cells in chronic myeloid leukemia (CML). Differentiation therapy is considered to be a new strategy for treating this type of leukemia. Aclacinomycin A (ACM) is an antitumor antibiotic. Previous studies ha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yueh-Lun, Chen, Chih-Wei, Liu, Fu-Hwa, Huang, Yu-Wen, Huang, Huei-Mei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3629111/ https://www.ncbi.nlm.nih.gov/pubmed/23613979 http://dx.doi.org/10.1371/journal.pone.0061939

Ejemplares similares

Correction: Aclacinomycin A Sensitizes K562 Chronic Myeloid Leukemia Cells to Imatinib through p38MAPK-Mediated Erythroid Differentiation
por: Lee, Yueh-Lun, et al.
Publicado: (2017)

Role of the aclacinomycin A--doxorubicin association in reversal of doxorubicin resistance in K562 tumour cells.
por: Millot, J. M., et al.
Publicado: (1989)

Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells
por: Arvaniti, Katerina, et al.
Publicado: (2014)

Induction of Erythroid Differentiation by 5‐Fluorouracil in K562 Leukemia Cells
por: Yang, Ya‐Wun, et al.
Publicado: (1995)

Cytotoxicity of Isoxazole Curcumin Analogs on Chronic Myeloid Leukemia-Derived K562 Cell Lines Sensitive and Resistant to Imatinib
por: Feriotto, Giordana, et al.
Publicado: (2023)

Rethinking Biosynthesis of Aclacinomycin A
por: Xu, Ziling, et al.
Publicado: (2023)

Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2014)

Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments
por: Zhao, Yan-hong, et al.
Publicado: (2017)

Correction: Wogonin induces cell cycle arrest and erythroid differentiation in imatinib-resistant K562 cells and primary CML cells
por: Yang, Hao, et al.
Publicado: (2020)

Integrative genomic analysis in K562 chronic myelogenous leukemia cells reveals that proximal NCOR1 binding positively regulates genes that govern erythroid differentiation and Imatinib sensitivity
por: Long, Mark D., et al.
Publicado: (2015)

Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells
por: Prado-Carrillo, Omar, et al.
Publicado: (2022)

Spred2 Modulates the Erythroid Differentiation Induced by Imatinib in Chronic Myeloid Leukemia Cells
por: Yang, Yuefeng, et al.
Publicado: (2015)

Apoptosis and autophagy have opposite roles on imatinib-induced K562 leukemia cell senescence
por: Drullion, C, et al.
Publicado: (2012)

MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
por: Wong, Shuit-Mun, et al.
Publicado: (2016)

Correction: MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells
por: Wong, Shuit-Mun, et al.
Publicado: (2017)

Cytotoxic Effects of Some Flavonoids and Imatinib on the K562 Chronic Myeloid Leukemia Cell Line: Data Analysis Using the Combination Index Method
por: Danışman Kalındemirtaş, Ferdane, et al.
Publicado: (2019)

Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia
por: Zheng, Cuiping, et al.
Publicado: (2014)

Inhibition of abl Oncogene Tyrosine Kinase Induces Erythroid Differentiation of Human Myelogenous Leukemia K562 Cells
por: Honma, Yoshio, et al.
Publicado: (1990)

Inhibition of p38 MAPK diminishes doxorubicin-induced drug resistance associated with P-glycoprotein in human leukemia K562 cells
por: Chen, Yinghui, et al.
Publicado: (2012)

Effects of THAP11 on Erythroid Differentiation and Megakaryocytic Differentiation of K562 Cells
por: Kong, Xiang-Zhen, et al.
Publicado: (2014)

Antiproliferative Effect of Aaptamine on Human Chronic Myeloid Leukemia K562 Cells
por: Jin, Meihua, et al.
Publicado: (2011)

Anticancer activity of Pupalia lappacea on chronic myeloid leukemia K562 cells
por: Ravi, Alvala, et al.
Publicado: (2012)

Tendency of K562 Chronic Myeloid Leukemia Cells Towards Cell Reprogramming
por: Yılmazer Aktuna, Açelya
Publicado: (2018)

The Effect of Polyhydroxy Fullerene Derivative on Human Myeloid Leukemia K562 Cells
por: Guo, Wei, et al.
Publicado: (2022)

hERG Potassium Channel Blockage by Scorpion Toxin BmKKx2 Enhances Erythroid Differentiation of Human Leukemia Cells K562
por: Ma, Jian, et al.
Publicado: (2013)

MicroRNA-223 reversibly regulates erythroid and megakaryocytic differentiation of K562 cells
por: Yuan, Jin-Yun, et al.
Publicado: (2009)

TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β-catenin/TCF7/ABC transporter signaling axis
por: Zhang, Hui, et al.
Publicado: (2021)

Unravelling pathways downstream Sox6 induction in K562 erythroid cells by proteomic analysis
por: Barbarani, Gloria, et al.
Publicado: (2017)

Inhibition of Skp2 Sensitizes Chronic Myeloid Leukemia Cells to Imatinib
por: Chen, Xiaowen, et al.
Publicado: (2020)

MiR-370 sensitizes chronic myeloid leukemia K562 cells to homoharringtonine by targeting Forkhead box M1
por: Zhou, MinRan, et al.
Publicado: (2013)

CDA gene silencing regulated the proliferation and apoptosis of chronic myeloid leukemia K562 cells
por: Wei, Xiao-Fang, et al.
Publicado: (2018)

HDAC1,2 Knock-Out and HDACi Induced Cell Apoptosis in Imatinib-Resistant K562 Cells
por: Chen, Shu-Huey, et al.
Publicado: (2019)

Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014)

New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells
por: Oliveira, Andressa, et al.
Publicado: (2022)

C(5) modified uracil derivatives showing antiproliferative and erythroid differentiation inducing activities on human chronic myelogenous leukemia K562 cells
por: Brognara, Eleonora, et al.
Publicado: (2011)

Effects of miR-210-3p on the erythroid differentiation of K562 cells under hypoxia
por: Hu, Caiyan, et al.
Publicado: (2021)

Alternative splicing of apoptosis-related genes in imatinib-treated K562 cells identified by exon array analysis
por: LIU, JING, et al.
Publicado: (2011)

Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors
por: Kuo, Yi-Hue, et al.
Publicado: (2021)

Inhibition of the Nrf2-TrxR Axis Sensitizes the Drug-Resistant Chronic Myelogenous Leukemia Cell Line K562/G01 to Imatinib Treatments
por: Xu, Lianrong, et al.
Publicado: (2019)

Induction of human chronic myeloid leukemia K562 cell apoptosis by virosecurinine and its molecular mechanism
por: ZHANG, GANG, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_bt5kued6joja3ppfagrsieuoeo